Navigation Links
BrainStorm Announces Second Quarter 2017 Financial Results
Date:8/14/2017

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June 30, 2017.

"We are in the advanced stages of preparing for our pivotal Phase 3 trial to investigate NurOwn® in ALS," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We have agreements with Mass. General Hospital, California Pacific Medical Center and University of California-Irvine Medical Center to participate as centers in the trial, which will be funded in part by a non-dilutive grant of $16 million awarded by the California Institute for Regenerative Medicine (CIRM).  Based on the body of preclinical and clinical data we have compiled on NurOwn®, including data from our placebo-controlled Phase 2 trial which showed evidence of halting in disease progression, we believe that NurOwn® has the potential to become a valuable treatment option for ALS patients."

Second Quarter and Recent Financial Highlights:

  • Entered into agreements with Massachusetts General Hospital, California Pacific Medical Center, and University of California-Irvine Medical Center to participate in the planned Phase 3 trial of NurOwn® in ALS, pending FDA and Institutional Review Board approvals.
  • Initiated technology transfer to City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn for the Phase 3 clinical study. City of Hope will be the clinical supplier for all U.S. medical centers participating in the trial.
  • Awarded a $16 million grant by the California Institute for Regenerative Medicine (CIRM) to support the Phase 3 NurOwn® trial.
  • Selected Worldwide Clinical Trials as the clinical research organization (CRO) for the Phase 3 NurOwn® trial.
  • Awarded a non-dilutive grant of approximately $2.1 million by the Israel Innovation Authority (IIA) (formerly called "the Office of the Chief Scientist) to support development of NurOwn®.
  • Appointed Mary Kay Turner as Vice President of Patient Advocacy and Government Affairs. Ms. Turner joins BrainStorm from Mitsubishi Tanabe Pharma America, where she supported the commercialization of edaravone (Radicava™) for ALS.
  • Announced publication of a preclinical study evaluating the use of NurOwn® in a mouse model of autism in the April issue of the journal Behavioural Brain Research.
  • Financial Results for the Second Quarter Ended June 30, 2017

  • Research and development expenses, net for the three months ended June 30, 2017 and 2016 were $435,000 and $151,000, respectively.
  • General and administrative expenses for the three months ended June 30, 2017 and 2016 were $640,000 and $832,000, respectively.
  • Net loss for the three months ended on June 30, 2017 was $ 1,040,000, as compared to a net loss of $962,000 for the three months ended June 30, 2016. Net loss per share for the three months ended June 30, 2017 and 2016 was $0.06 and $0.05, respectively.
  • At June 30, 2017, the Company had net working capital of $6,971,000 including cash, cash equivalents and short-term bank deposits amounting to $6,717,000.
  • Financial Results for the Six Months Ended June 30, 2017

  • Research and development expenses, net for the six months ended June 30, 2017 and 2016 were $1.4 million and $1.1 million, respectively.
  • General and administrative expenses for the six months ended June 30, 2017 and 2016 were $1.5 million and $1.7 million respectively.
  • Net loss for the six months ended on June 30, 2017 was $2.8 million, as compared to a net loss of $2.8 million for the six months ended June 30, 2016. Net loss per share for the six months ended June 30, 2017 and 2016 was $0.15 and $0.15, respectively.
  • Conference Call on Wednesday, August 16thMembers of BrainStorm's senior management team, including Chaim Lebovits, CEO, and Ralph Kern, M.D., MHSc, COO and CMO, will host a conference call and live webcast for the investment community on Wednesday, August 16, 2017 at 8:30am Eastern Time.  The details are as follows:  Toll Free:                   877-718-5095  
    Israel Investors:        1 80 924 6042  
    International:             913-312-0381  
    Conference ID:          1392963  
    Webcast:                   http://public.viavid.com/index.php?id=125868

    Replays, available through August 30, 2017  
    Toll Free:                   844-512-2921  
    International:             412-317-6671  
    Conference ID:          1392963

    About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

    Safe-Harbor Statement         Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

    CONTACTS
    Media:
    Uri Yablonka
    Chief Business Officer
    BrainStorm Cell Therapeutics Inc.
    Phone: 646-666-3188
    uri@brainstorm-cell.com

    Investors:
    Michael Rice
    LifeSci Advisors, LLC
    Phone: 646-597-6979
    mrice@lifesciadvisors.com

     

    BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESINTERIM CONDENSED CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data) June 30,December 31,2 0 1 72 0 1 6U.S. $ in thousands ASSETSUnauditedAuditedCurrent Assets:Cash and cash equivalents

    $        5,784

    $           547Short-term deposit (Note 4)

    933

    9,443Account receivable

    735

    306Prepaid expenses and other current assets

    230

    148Total current assets7,682

    10,444Long-Term Assets:Prepaid expenses and other long-term assets

    24

    25Property and Equipment, Net 

    295

    297Total Long-Term Assets319

    322Total assets$       8,001

    $      10,766LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities:Accounts payables

    $         227

    $         345Accrued expenses

    114

    152Other accounts payable

    370

    367Total current liabilities 711

    864Stockholders' Equity:Stock capital: (Note 5)

    11

    11Common stock of $0.00005 par value - Authorized: 100,000,000 shares at June 30, 2017 and December 31, 2016 respectively; Issued and outstanding: 18,747,327 and 18,687,987 shares at June 30, 2017 and December 31, 2016 respectively.Additional paid-in-capital

    85,227

    85,014Accumulated deficit

    (77,948)

    (75,123)Total stockholders' equity7,290

    9,902Total liabilities and stockholders' equity$        8,001

    $     10,766


     

    BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESINTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)U.S. dollars in thousands(Except share data) Six months endedThree months endedJune 30,June 30,201720162 0 1 72 0 1 6UnauditedUnauditedOperating expenses:Research and development, net

    $       1,376

    $       1,137

    $      435

    $      151General and administrative

    1,469

    1,658

    640

    832Operating loss                                                    (2,845)

    (2,795)

    (1,075)

    (983)Financial income, net

    (20)

    (43)

    (35)

    (21)Net loss$     (2,825)

    $     (2,752)

    $      (1,040)

    $      (962)Basic and diluted net profit (loss) per share

     

    $   (0.15)

    $        (0.15)

     

    $        (0.06)

     

    $        (0.05)Weighted average number of shares outstanding used in computing basic and diluted net loss per share

     

    18,713,575

     

    18,653,922

     

    18,738,496

     

    18,654,040

     

    View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-announces-second-quarter-2017-financial-results-300503783.html


    '/>"/>
    SOURCE BrainStorm Cell Therapeutics Inc.
    Copyright©2017 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
    2. BrainStorm Cell Therapeutics Chief Scientific Advisor to Present At The 2015 FENS-RM in Thessaloniki, Greece
    3. BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
    4. BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
    5. Latest Updates on Health Care Sector: Special Research on bluebird bio, Brainstorm, CASI Pharmaceuticals, Celladon, and Cellular Dynamics
    6. Cannabis Science Highlights Additional Attendees at the Washington DC, African Union, CFA African Healthcare Infrastructure Forum and Brainstorm on February 6, 2015
    7. Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2017
    8. Diplomat Announces A New President
    9. Diplomat Announces 2nd Quarter Financial Results
    10. Endo Announces Agreements to Resolve Virtually All Known U.S. Mesh Product Liability Claims
    11. West Announces Second-Quarter 2017 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
    (Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
    (Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
    Breaking Medicine Technology:
    (Date:9/21/2017)... ... September 21, 2017 , ... The American ... Health Services for professionals in the addiction treatment industry entitled: Special Investigations ... , Insurance companies and state and federal governments are increasingly scrutinizing the addiction ...
    (Date:9/21/2017)... ... 21, 2017 , ... Hair restoration surgery is having a ... the International Society of Hair Restoration Surgery (ISHRS). The worldwide volume ... with 635,189 procedures performed in 2016. , "Like other forms of cosmetic ...
    (Date:9/21/2017)... , ... September 21, 2017 , ... Bill Howe Plumbing’s ... its customers, and give back to the community. For over 37 years, they have ... successful companies serving plumbing in San Diego. They were chosen as the ...
    (Date:9/21/2017)... ... September 21, 2017 , ... Innovatum ... at the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, ... ensuring label quality and improving patient safety. , Microscan , a ...
    (Date:9/21/2017)... ... September 21, 2017 , ... ... and highly accurate cancer screening tests, has received two prestigious recognitions that acknowledge ... survival rates. , Preora has been named a Top 100 Finalist ...
    Breaking Medicine News(10 mins):